Typhaneoside suppresses osteoclastogenesis and osteoporosis by stabilizing ADORA1.

BACKGROUND Osteoporosis, characterized by impaired bone remodeling and increased bone fragility, is increasingly prevalent among postmenopausal women. Current pharmacological treatments exhibit efficacy but are associated with adverse effects, prompting interest in natural flavonoids like Typhaneoside, known for anti-inflammatory and antioxidant properties. However, the molecular mechanism by which TYP influences osteoclast differentiation remains unclear. PURPOSE This study aims to investigate the anti-osteoporotic effect of TYP and elucidate its underlying molecular mechanisms involving osteoclast differentiation and activity. STUDY DESIGN RANKL-induced osteoclast differentiation models in mouse bone marrow-derived monocytes (BMMCs) and ovariectomy (OVX)-induced osteoporosis mouse models were utilized to assess the effect of TYP on bone metabolism in vitro and in vivo. METHODS The effects of TYP on osteoclast differentiation and function were evaluated by TRAP staining, qRT-PCR, Western blot, immunoprecipitation, molecular docking, and mass spectrometry. Micro-CT, histological staining, and biochemical assays were performed to evaluate bone structure and metabolism in OVX mice. RESULTS TYP significantly inhibited RANKL-induced osteoclast differentiation and bone resorption activity without cytotoxic effects in vitro. In OVX mice, TYP treatment dose-dependently improved bone microarchitecture, reduced osteoclast numbers, and decreased serum bone resorption markers. Mechanistically, TYP directly bound ADORA1 receptor at the LYS265 site, competitively inhibiting NEDD4-1-mediated ubiquitination, thus stabilizing ADORA1 and suppressing osteoclast-specific gene expression (TRAP, CTSK, NFATc1). CONCLUSION These findings reveal that TYP effectively attenuates osteoclast differentiation and activity by stabilizing ADORA1 via inhibition of NEDD4-1-mediated ubiquitination, suggesting its therapeutic potential for osteoporosis treatment.

• Publication year

  2026

• Venue

  Phytomedicine

• Publication date

  2026-01-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.phymed.2026.157817PMID 41576610
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Ginseng in delaying brain aging: Progress and Perspectives.

  2025cited by this paper
• Multiple Enzymes Expressed by the Gut Microbiota Can Transform Typhaneoside and Are Associated with Improving Hyperlipidemia

  2025cited by this paper
• Cell signaling and transcriptional regulation of osteoblast lineage commitment, differentiation, bone formation, and homeostasis

  2024cited by this paper
• Role of ubiquitination in the occurrence and development of osteoporosis (Review)

  2024cited by this paper
• Astragali Radix-Curcumae Rhizoma herb pair reduces the stemness of colorectal cancer cells through HIF-2α/β-catenin pathway.

  2024cited by this paper
• Attenuating bone loss in osteoporosis: the potential of corylin (CL) as a therapeutic agent

  2024cited by this paper
• Desulfovibrio vulgaris interacts with novel gut epithelial immune receptor LRRC19 and exacerbates colitis

  2024cited by this paper
• Bone Targeting Nanoparticles for the Treatment of Osteoporosis

  2024cited by this paper
• Angelica sinensis polysaccharide could alleviate the gastrointestinal damage in alcoholic fatty liver disease mice: Regulation of alcohol metabolism and enhancement of short-chain fatty acids utilization.

  2024cited by this paper
• Adenosine receptor A1 enhanced mitochondrial biogenesis and exerted neuroprotection after cerebral ischemia through PGC-1α

  2023cited by this paper
• Mangiferin attenuates osteoporosis by inhibiting osteoblastic ferroptosis through Keap1/Nrf2/SLC7A11/GPX4 pathway.

  2023cited by this paper
• Sex Specific Global Burden of Osteoporosis in 204 Countries and Territories, from 1990 to 2030: An Age-Period-Cohort Modeling Study

  2023cited by this paper
• Hepatoprotective effect of Typhaneoside on non-alcoholic fatty liver disease via farnesoid X receptor in vivo and in vitro.

  2023cited by this paper
• OTUB1 promotes osteoblastic bone formation through stabilizing FGFR2

  2023cited by this paper
• Chondrogenic differentiation of rat bone marrow mesenchymal stem cells induced by puerarin and tetrandrine

  2022cited by this paper
• Efficacy and Safety of Shenfu Injection for Severe Pneumonia in the Elderly: A Systematic Review and Meta-Analysis Based on Western and Eastern Medicine

  2022cited by this paper
• Baohuoside I Inhibits Osteoclastogenesis and Protects Against Ovariectomy-Induced Bone Loss

  2022cited by this paper
• Beraprost ameliorates postmenopausal osteoporosis by regulating Nedd4-induced Runx2 ubiquitination

  2021cited by this paper
• Oroxin B Attenuates Ovariectomy-Induced Bone Loss by Suppressing Osteoclast Formation and Activity

  2021cited by this paper
• Flavonoids: Classification, Function, and Molecular Mechanisms Involved in Bone Remodelling

  2021cited by this paper
• The SQSTM1/p62 UBA domain regulates Ajuba localisation, degradation and NF-κB signalling function

  2021cited by this paper
• E3 Ubiquitin Ligase-Mediated Regulation of Osteoblast Differentiation and Bone Formation

  2021cited by this paper
• Bisphosphonate-Based Conjugates and Derivatives as Potential Therapeutic Agents in Osteoporosis, Bone Cancer and Metastatic Bone Cancer

  2021cited by this paper
• Typhaneoside Suppresses Glutamate Release Through Inhibition of Voltage-Dependent Calcium Entry in Rat Cerebrocortical Nerve Terminals.

  2021cited by this paper
• The relationship between bone marrow adipose tissue and bone metabolism in postmenopausal osteoporosis.

  2020cited by this paper
• ADORA1 Inhibition Promotes Tumor Immune Evasion by Regulating the ATF3-PD-L1 Axis.

  2020cited by this paper
• Selective activation of Gαob by an adenosine A1 receptor agonist elicits analgesia without cardiorespiratory depression

  2020cited by this paper
• Pyrroloquinoline Quinone Prevents Estrogen Deficiency-Induced Osteoporosis by Inhibiting Oxidative Stress and Osteocyte Senescence

  2019cited by this paper
• Therapeutic Anabolic and Anticatabolic Benefits of Natural Chinese Medicines for the Treatment of Osteoporosis

  2019cited by this paper
• Decoding WW domain tandem-mediated target recognitions in tissue growth and cell polarity

  2019cited by this paper
• Typhaneoside prevents acute myeloid leukemia (AML) through suppressing proliferation and inducing ferroptosis associated with autophagy.

  2019cited by this paper
• Effect of typhaneoside on ventricular remodeling and regulation of PI3K/Akt/mTOR pathway

  2019cited by this paper
• Targeting therapeutics to bone by conjugation with bisphosphonates

  2018cited by this paper
• Boldine Ameliorates Estrogen Deficiency-Induced Bone Loss via Inhibiting Bone Resorption

  2018cited by this paper
• Oxidative stress as a possible pathogenic cofactor of post-menopausal osteoporosis: Existing evidence in support of the axis oestrogen deficiency-redox imbalance-bone loss

  2018cited by this paper
• Blocking of the Ubiquitin-Proteasome System Prevents Inflammation-Induced Bone Loss by Accelerating M-CSF Receptor c-Fms Degradation in Osteoclast Differentiation

  2017cited by this paper
• Molecular signaling mechanisms behind polyphenol-induced bone anabolism

  2017cited by this paper
• Ubiquitin E3 ligase Itch negatively regulates osteoblast function by promoting proteasome degradation of osteogenic proteins

  2017cited by this paper
• Antioxidant capacity of Typha angustifolia extracts and two active flavonoids

  2017cited by this paper
• An overview and management of osteoporosis.

  2017cited by this paper
• Therapeutic Potential and Outlook of Alternative Medicine for Osteoporosis.

  2017cited by this paper
• Safety and effectiveness of daily teriparatide for osteoporosis in patients with severe stages of chronic kidney disease: post hoc analysis of a postmarketing observational study

  2016cited by this paper
• Biology of Bone Tissue: Structure, Function, and Factors That Influence Bone Cells

  2015cited by this paper
• Simultaneous Determination of Typhaneoside and Isorhamnetin-3-O-Neohesperidoside in Rats After Oral Administration of Pollen Typhae Extract by UPLC-MS/MS.

  2015cited by this paper
• Simultaneous determination of paeoniflorin, albiflorin, ferulic acid, tetrahydropalmatine, protopine, typhaneoside, senkyunolide I in Beagle dogs plasma by UPLC-MS/MS and its application to a pharmacokinetic study after Oral Administration of Shaofu Zhuyu Decoction.

  2014cited by this paper
• M-CSF Potently Augments RANKL-Induced Resorption Activation in Mature Human Osteoclasts

  2011cited by this paper
• Smurf control in bone cells

  2010cited by this paper
• Adenosine A(1) receptors regulate bone resorption in mice: adenosine A(1) receptor blockade or deletion increases bone density and prevents ovariectomy-induced bone loss in adenosine A(1) receptor-knockout mice.

  2010cited by this paper
• Negative Feedback Control of Osteoclast Formation through Ubiquitin-mediated Down-regulation of NFATc1*

  2009cited by this paper
• Sequestosome 1 Mutations in Paget's Disease of Bone in Australia: Prevalence, Genotype/Phenotype Correlation, and a Novel Non‐UBA Domain Mutation (P364S) Associated With Increased NF‐κB Signaling Without Loss of Ubiquitin Binding

  2009cited by this paper
• A Novel Mutation (K378X) in the Sequestosome 1 Gene Associated With Increased NF‐κB Signaling and Paget's Disease of Bone With a Severe Phenotype

  2006cited by this paper
• The kinase Grk2 regulates Nedd4/Nedd4-2-dependent control of epithelial Na+ channels.

  2004cited by this paper
• Mediation of tubuloglomerular feedback by adenosine: Evidence from mice lacking adenosine 1 receptors

  2001cited by this paper
• A1 adenosine receptor antagonists block ischemia-reperfusion injury of the heart.

  1996cited by this paper

• No citing papers are available for this paper.